Switch theme
Sign up to access all valuation multiples
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
1980
28K+
LTM Revenue $33.7B
LTM EBITDA $19.9B
$211B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amgen has a last 12-month revenue of $33.7B and a last 12-month EBITDA of $19.9B.
In the most recent fiscal year, Amgen achieved revenue of $33.4B and an EBITDA of $13.4B.
Amgen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amgen valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $26.3B | $28.2B | $33.4B | $33.7B | XXX |
| Gross Profit | $19.9B | $19.7B | $20.6B | XXX | XXX |
| Gross Margin | 76% | 70% | 62% | XXX | XXX |
| EBITDA | $12.2B | $14.8B | $13.4B | $19.9B | XXX |
| EBITDA Margin | 46% | 53% | 40% | 59% | XXX |
| Net Profit | $6.6B | $6.7B | $4.1B | XXX | XXX |
| Net Margin | 25% | 24% | 12% | XXX | XXX |
| Net Debt | $31.3B | $53.7B | $48.1B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Amgen's stock price is $303.
Amgen has current market cap of $163B, and EV of $211B.
See Amgen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $211B | $163B | XXX | XXX | XXX | XXX | $19.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Amgen has market cap of $163B and EV of $211B.
Amgen's trades at 6.3x LTM EV/Revenue multiple, and 10.6x LTM EBITDA.
Analysts estimate Amgen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Amgen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $211B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 15.8x | XXX | XXX | XXX |
| P/E | 39.8x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 20.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAmgen's NTM/LTM revenue growth is 5%
Amgen's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Amgen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Amgen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Amgen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 45% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 40% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amgen acquired XXX companies to date.
Last acquisition by Amgen was XXXXXXXX, XXXXX XXXXX XXXXXX . Amgen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Amgen founded? | Amgen was founded in 1980. |
| Where is Amgen headquartered? | Amgen is headquartered in United States of America. |
| How many employees does Amgen have? | As of today, Amgen has 28K+ employees. |
| Who is the CEO of Amgen? | Amgen's CEO is Mr. Robert A. Bradway. |
| Is Amgen publicy listed? | Yes, Amgen is a public company listed on NAS. |
| What is the stock symbol of Amgen? | Amgen trades under AMGN ticker. |
| When did Amgen go public? | Amgen went public in 1983. |
| Who are competitors of Amgen? | Similar companies to Amgen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amgen? | Amgen's current market cap is $163B |
| What is the current revenue of Amgen? | Amgen's last 12-month revenue is $33.7B. |
| What is the current EBITDA of Amgen? | Amgen's last 12-month EBITDA is $19.9B. |
| What is the current EV/Revenue multiple of Amgen? | Current revenue multiple of Amgen is 6.3x. |
| What is the current EV/EBITDA multiple of Amgen? | Current EBITDA multiple of Amgen is 10.6x. |
| What is the current revenue growth of Amgen? | Amgen revenue growth between 2023 and 2024 was 19%. |
| Is Amgen profitable? | Yes, Amgen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
